Skip to main content
. Author manuscript; available in PMC: 2016 Dec 9.
Published in final edited form as: Br J Ophthalmol. 2015 Apr 14;99(10):1366–1371. doi: 10.1136/bjophthalmol-2014-306364

Table 2. Neoadjuvant Chemotherapy Regimens.

Chemotherapy Regimen* Number of Patients Number (range) of Courses
Carboplatin 1 8
Carboplatin/Etoposide (CE) 1 6
Vincristine/Doxorubicin/Cyclophosphamide alternating with CE 1 6
Intra-arterial Topotecan and Melphalan 1 4
Vincristine/Carboplatin (VC) 36 8 (2-8)
Vincristine/Carboplatin/Etoposide 11 6 (5-12)
Vincristine/Topotecan alternating with VC including Subconjunctival Carboplatin 9 VT: 5 (1-5)\VC: 6 (2-8)
*

Carboplatin (Paraplatin ®); Etoposide (VePesid ® or Toposar ®); Topotecan (Hycamtin ®); Cyclophosphamide (Cytoxan ®); Vincristine (Oncovin ®); Doxorubicin (Adriamycin ® or Rubex ®); Melphalan (Alkeran ®)